A trial of oral immunotherapy in children and adolescents highly allergic to peanut, treated with AR101 resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms according to research published yesterday.
To see the RTE news clip featuring an Irish participant and commentary from Professor Hourihane, Paediatric Allergist at Cork University Hospital and Principal Investigator at the INFANT Centre at University College Cork, who led the Irish leg of the trial click on the Twitter link below or here
This is very positive news for children and families affected by peanut allergy and has generated huge interest in the prospect of a “cure” for peanut allergy.
Prof. Hourihane is very keen to clarify that this study is not about curing peanut allergy and wishes to advise that only children, not adults, can be recruited. At present there are no studies open. If/when there are, only children that have been fully evaluated in the existing paediatric clinical services at Cork University Hospital are eligible to be considered for inclusion and that the only route to accessing existing clinical services at Cork University Hospital is through routine referral via GP’s.
A trial of a new therapy shows a reduction in the effects of peanut allergy pic.twitter.com/CXkdj6pBYe
— RTÉ News (@rtenews) November 19, 2018